Patient Recruitment

TriNetX Signs Agreement with FDA Sentinel Program | PR Newswire | 7/14/2020

… data to make clinical and observational research easier and more efficient. TriNetX combines real time access to longitudinal clinical data with state-of-the-art analytics to optimize protocol design and feasibility, site selection, patient recruitment , and enable discoveries through the generation of real-world evidence. The TriNetX platform is HIPAA and GDPR compliant. For more information, visit TriNetX at www.trinetx.com or follow @TriNetX on Twitter. About Harvard Pilgrim Health …

Alligator Bioscience AB (publ) Interim Report January-June 2020 | PR Newswire | 7/13/2020

… build value of the clinical drug candidates, while reducing preclinical expenses including a 20% reduction in workforce. The adjustments will extend Alligator’s cash runway into the fourth quarter of 2021. Effects of Covid-19 : Patient recruitment in the Phase I studies was temporarily paused in March and April 2020 due to the Covid-19 pandemic but has been resumed. Approved governmental subsidies amount to SEK 1.5 to 2.0 million. Financial …

Follow Patient Recruitment:    

ASLAN Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update | Globe Newswire | 7/13/2020

… 19 restrictions gradually lift in Singapore we expect to resume recruitment into our multiple ascending dose (MAD) study of ASLAN004 in early August. With the continuing impact of COVID-19 causing some delays in patient recruitment , we plan to share further data from the trial during the fourth quarter of 2020. We have been proactive in preparing to open new study sites in Australia and the US to ensure we …

Craig Lipset Joins Transparency Life Science Advisory Board | The Wapakoneta Daily News | 7/13/2020

… then analyzed using AI-enabled natural language processing and TLS’ proprietary advanced analytic tools to help sponsors draft protocols more relevant to patient needs and clinical practice, which can help expedite both investigator and patient recruitment , resulting in fewer patients failing to complete a study and enhanced data quality. The technology, once implemented, can also help understand patient behavior utilizing historical data thereby enhancing engagement. “We’ve seen an evolution in …

Industry Experts Share Insights on Running Trials During the Pandemic and Beyond | 2020-07-12 | CenterWatch | 7/13/2020

Attendees at the recent MAGI Clinical Cloud Conference heard advice from a variety of industry experts on running clinical trials now and into the “new normal.” The following is a selection of speakers’ thoughts on subjects from patient recruitment to negotiating clinical trial agreements (CTA). Subject recruitment is one of many areas of clinical research being affected by the current COVID-19 pandemic. Some sponsors and sites halted recruitment when …

Clinical Research Representative – Santa Ana | 7/13/2020

… electronic trial master file), CTMS (clinical trial management system) and ensure compliance with internal procedures. May review clinical data for completeness for multiple clinical research trials (40%) Collate new study materials, create study binders, patient recruitment materials, and arrange shipment of materials to clinical sites (15%) H.S. Diploma with 2 years of previous related experience required. Bachelor’s Degree preferred. Experience with TMF/ETMF- minimum 2 years experience (Veeva highly preferred …

Craig Lipset Joins Transparency Life Science Advisory Board | Business & Finance | manchestertimes.com | Business Wire | 7/13/2020

… then analyzed using AI-enabled natural language processing and TLS’ proprietary advanced analytic tools to help sponsors draft protocols more relevant to patient needs and clinical practice, which can help expedite both investigator and patient recruitment , resulting in fewer patients failing to complete a study and enhanced data quality. The technology, once implemented, can also help understand patient behavior utilizing historical data thereby enhancing engagement. “We’ve seen an evolution in …

Opportunity for M.Pharm as Clinical Operations Manager at Dr. Reddy’s Laboratories | 7/12/2020

… and Injectables) and differentiated products for developed as well as Emerging markets. • Planning and execution of clinical studies, monitoring and conducting the clinical development operation activities (protocol finalisation, site selection, site monitoring, study plans, patient recruitment , Data Management, Biostatistics, study report finalisation) and resolving complex issues with respect to conduct of clinical and patient based pharmacokinetic studies • Work closely with product development teams, preclinical & clinical, regulatory and medical teams for …

Clinical Research Coordinator - Nephrology - Columbia University - , NY | 7/11/2020

… a Hours Per Week: 35 Salary Range: Commensurate with experience Position Summary The Clinical Research Coordinator (CRC) will provide support for research activities in the Division of Nephrology. S/he will be responsible for patient recruitment for genetic and non-genetic studies, including obtaining informed consent and administering standardized questionnaires. Responsibilities Performs collection of biosamples, including kidney biopsy tissue and clinical information and follow-up data from medical records. Schedules …

AGENT Study Update With Regards to COVID-19 | PR Newswire | 7/10/2020

PRNewswire/ – Isofol Medical AB (publ) (Nasdaq First North Premier Growth Market: ISOFOL), informs that the outbreak of COVID-19 has affected the general situation of the AGENT study activities. Patient recruitment has been ongoing without interruption during the pandemic, but the effects of COVID-19 may result in a delay of the full enrolment by up to three months. As hospitals, regions and countries have updated their guidelines, Isofol has …

DCC Ascendent Joins Clinerion’s Patient Network Explorer Platform and Improves Access to Leading-Edge Healthcare Treatment Options for Patients and Physicians in Bulgaria | PRWeb | 7/9/2020

… protocol optimization, site feasibility evaluation and real-time patient search and identification to match patients to treatments. Clinerion facilitates the participation of partner hospitals in leading-edge, industry-sponsored trials and time savings in patient recruitment . Researchers gain access to real-time, longitudinal patient data from electronic health records for analysis. We enable pharmaceutical companies, CROs and SMOs to shorten patient recruitment and save costs by streamlining operations and leveraging …

JBR Clinical Research Surgical Center Earns Prestigious AAAASF Accreditation | PR Newswire | 7/9/2020

… Clinical Research ( www.cenexelresearch.com ) provides unparalleled medical and scientific support in the design and execution of clinical trials. The attention to detail assures quality, reliable results and has helped CenExel to consistently achieve and exceed patient recruitment goals. CenExel Centers of Excellence have conducted thousands of studies, the variety and complexity of which have resulted in a vast depth of experience and insight for the principal investigators and research staff in …

Ripple Science Partners with Lakeside Life Science to Accelerate the Clinical Validation Process for Medsential’s Point-of-Care COVID-19 Antibody Test | PRWeb | 7/9/2020

… team to bring quality products to global markets. About Ripple Science: Ripple Science accelerates clinical research with its secure, HIPAA-compliant suite of tools. By adapting sales and marketing automation to the process of patient recruitment , Ripple helps our customers recruit more participants, faster and reduces patients lost to follow-up. Ripple Science’s flagship product, Ripple, is currently being used by research investigators at more than 100 academic and research …

Palatin Technologies, Inc. Announces Reinitiation of Enrollment of Phase 2 Study with PL9643 for the Treatment of Dry Eye Disease | PR Newswire | 7/8/2020

… that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced reinitiation of enrollment of its Phase 2 study with PL9643 for the treatment of dry eye disease (DED). After pausing patient recruitment to ensure patient safety during the initial phases of the COVID-19 pandemic, Palatin has commenced patient recruitment in its PL9643 Phase 2 clinical study in subjects with dry eye disease. Patient enrollment is …

Palatin Reinitiates Enrollment Of Phase 2 Study With PL9643 To Treat Dry Eye Disease | 7/8/2020

Biopharmaceutical company Palatin Technologies, Inc. ( PTN ) announced Wednesday the reinitiation of enrollment of its Phase 2 clinical study with PL9643 for the treatment of dry eye disease (DED). The company had paused patient recruitment to ensure patient safety during the initial phases of the COVID-19 pandemic. Patient enrollment is currently expected to be complete within the next 30-45 days, with data readout targeted for the fourth quarter of calendar …

Edited Transcript of INFI.OQ earnings conference call or presentation 11-May-20 8:30pm GMT | Yahoo News | 7/8/2020

… are working closely with our CRO and investigators to address. By working with sites and investigators to leverage early site initiation and enrollment experience, insights can be generated to inform new site initiation and patient recruitment initiatives. Though COVID-19 has limited our access to sites over the past few months and made this work more challenging, we have identified and are implementing initiatives designed to accelerate site initiation and …

Palatin Technologies Announces Reinitiation of Enrollment of Phase 2 Study With PL9643 for the Treatment of Dry Eye Disease | 7/8/2020

… PL9643 for the Treatment of Dry Eye Disease Source: Palatin Technologies Palatin Technologies announced reinitiation of enrollment of its phase 2 study with PL9643 for the treatment of dry eye disease (DED). After pausing patient recruitment to ensure patient safety during the initial phases of the COVID-19 pandemic, Palatin has commenced patient recruitment in its PL9643 phase 2 clinical study in subjects with dry eye disease. Patient enrollment is …

Signant Health Names Roger Smith CEO | PR Newswire | 7/8/2020

… solutions. In his role, Mr. Smith was responsible for AES’s strategic direction and financial growth as its chief executive, and played a pivotal role working closely with research sites and pharmaceutical organizations to solve patient recruitment challenges by utilizing digital technology and data science. Prior to joining PPD in 2013 through its acquisition of Acurian, Mr. Smith held a number of senior management positions for Acurian, Kozmo.com and Sony Corporation …

Characterisation of microbiota in saliva, bronchoalveolar lavage fluid, non-malignant, peritumoural and tumour tissue in non-small cell lung cancer patients: a cross-sectional clinical trial | 7/8/2020

… to put in perspective the relation with and between lung samples. As a second objective, we investigated whether tumour location in the UL or LL yields significant changes in these microbiota. Methods and patients Patient recruitment and study design All patients were enrolled in a prospective study, approved by the CPP Sud Est VI Ethics Committee and registered at ClinicalTrials.gov (NCT03068663) [ 34 ]. Written informed consent was obtained from all patients …

5 Q’s for Charles Fisher, CEO of Unlearn.AI | 7/7/2020

… Innovation spoke with Charles Fisher, chief executive officer and founder of Unlearn.AI , a U.S. firm that uses AI to build digital replicas of patients in clinical trials. Fisher discussed how this approach can address patient recruitment , one of the main challenges associated with trials for diseases like Alzheimer’s. Eline Chivot: What has led you to build Unlearn.AI? How is your approach to clinical trials different from traditional solutions? Charles Fisher …

Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease | BMJ | 7/7/2020

… control subjects (non-NAFLD). Adopting a case–control design, we ensured that the control liver samples matched patients’ features in each cohort (morbidly obese and non-morbidly obese). Complete details of the study design, patient recruitment strategy, physical, anthropometric and biochemical evaluation, as well as histological assessment are shown in the online supplementary material . Supplementary data All investigations performed as a part of the present study were conducted in accordance …

Excelya Welcomes Three European Contract Research Organizations to Become One Stop Provider Throughout Europe | Business Wire | 7/6/2020

… Zeincro has developed a thorough understanding of the communities and the regions in which it operates. This approach allows ZEINCRO to set new standards for successful clinical trials by delivering bespoke services that maximize patient recruitment and compliance. For more information, please visit zeincro.com . About Koehler eClinical GmbH Koehler eClinical GmbH is a mid-size specialty CRO with more than 25 years of experience in providing value-added services for …

NeoDynamics restarts patient recruitment to UK COMPULSE Study to optimize diagnosis of breast cancer | 7/6/2020

STOCKHOLM - July 6, 2020. NeoDynamics AB (Spotlight Stock Market: NEOD), announces that the Company restarts patient recruitment to the UK COMPULSE Study following a temporary pause imposed by the COVID-19 pandemic. COMPULSE is a comparative study to investigate the potential benefits of NeoNavia, the first pulse biopsy system, compared to current standard of practice. It is a follow-on study derived from the ongoing German PULSE study. Patient recruitment …

AVROBIO Announces New Patients Dosed in Gaucher Disease and Cystinosis Clinical Trials | Business & Finance | heraldchronicle.com | Business Wire | 7/6/2020

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jul 6, 2020– AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the first patient has been dosed in the company’s GuardOne clinical trial , a Phase 1/2 investigational study evaluating AVR-RD-02 for Gaucher disease type 1. The company also announced that the second patient has been dosed …

Trialbee Partners with Datavant to Power Patient-Centric Clinical Trial Recruitment and Engagement | 7/4/2020

… partnership with Datavant, the leader in privacy-protecting data connectivity, to more effectively and efficiently recruit clinical trial participants. “We are solving for the Investigator fatigue and demotivation caused by unguided mega screening for patient recruitment and the low results it produces,” said Lollo Eriksson, chief executive officer of Trialbee. “This partnership with Datavant will significantly expand our access to real world data (RWD) and ability to choose the information …

COVID-19

TriNetX Signs Agreement with FDA Sentinel Program | PR Newswire | 7/14/2020

… leveraging the TriNetX platform to access RWD and conduct in-depth analyses to monitor the use of critical drugs for COVID-19 patients in an effort to monitor potential drug shortages and to better understand … art analytics to optimize protocol design and feasibility, site selection, patient recruitment, and enable discoveries through the generation of real-world evidence. The TriNetX platform is HIPAA and GDPR compliant. For more information, visit TriNetX …

AACR

Alligator Bioscience AB (publ) Interim Report January-June 2020 | PR Newswire | 7/13/2020

… development portfolio. ATOR-1015 has received a great deal of attention in connection with the positive interim data presented at AACR and ASCO, the world’s two largest oncology conferences. We have also worked actively with … into the fourth quarter of 2021. Effects of Covid-19 : Patient recruitment in the Phase I studies was temporarily paused in March and April 2020 due to the Covid-19 pandemic but has been resumed …

Biopharma

Craig Lipset Joins Transparency Life Science Advisory Board | Business & Finance | manchestertimes.com | Business Wire | 7/13/2020

… to help sponsors draft protocols more relevant to patient needs and clinical practice, which can help expedite both investigator and patient recruitment, resulting in fewer patients failing to complete a study and enhanced data quality … the P.I.s.” Lipset is a growth advisor to technology and biopharmaceutical companies, leading universities, and the venture community, bringing vision and driving action at the intersection of research, digital solutions, and patient engagement. He was …

Clinical Research

JBR Clinical Research Surgical Center Earns Prestigious AAAASF Accreditation | PR Newswire | 7/9/2020

JBR Clinical Research Surgical Center Earns Prestigious AAAASF Accreditation Safety and Quality are Paramount at CenExel Research Facility News provided by Jul 09, 2020, 07:25 ET Share this article SALT LAKE CITY , July 9, 2020 … results and has helped CenExel to consistently achieve and exceed patient recruitment goals. CenExel Centers of Excellence have conducted thousands of studies, the variety and complexity of which have resulted in a vast depth of …

Health Research

SETD1B-associated neurodevelopmental disorder | BMJ | 6/26/2020

… BC, MD and MC all contributed patient cases and contributed to manuscript revisions. Additionally, MD and MC assisted in initial patient recruitment to the EPGEN study and provided neurological expertise in describing the cases. JM … funded by BC Children’s Hospital Intramural Funds, Canadian Institutes of Health Research (project grant: PJT-148695, PJT-148830). WTG’s salary is supported by the BC Children’s Hospital Foundation through their Investigator Grant Award Program (IGAP …

Food and Drug Administration

ReNeuron Provides Program and Regulatory Approvals Update | PR Newswire | 6/17/2020

… based therapy programs. On February 24, 2020 , the Company announced that it had submitted a protocol amendment to the U.S. Food and Drug Administration (FDA) to expand the ongoing Phase 2a clinical study of its … build on the clinical data already generated in the US. Patient recruitment in the PISCES III Phase 2b study with CTX in stroke disability, which has been on hold due to COVID-19 related restrictions …

National Institutes of Health

Science 37® Partners with Advarra to Expedite Virtual Trial Research for COVID-19 | PR Newswire | 4/21/2020

… reviews that are fully coordinated with IRB reviews, plus an IBC-ready model that can help sites register with the National Institutes of Health and reduce start-up time. These capabilities, when combined with the … partner with Science 37 to help expedite COVID-19 trials.” Patient recruitment and retention are being dramatically impacted by the COVID-19 pandemic, and as a result, trial sponsors are developing risk mitigation strategies to …

CDC

Otonomy Provides Business Update Related to COVID-19 Pandemic | Globe Newswire | 4/9/2020

… in line with directives from the State of California and guidance from the U.S. Centers for Disease Control and Prevention (CDC). On-site activities have been restricted to certain essential facility and laboratory support functions … release include, but are not limited to, timing of results, patient recruitment and enrollment plans and activity for, design and conduct of, data collection and preservation of data integrity with respect to, and the risks …

Biotech

GENFIT adapts its activities to the coronavirus | Yahoo News | 3/31/2020

… coronavirus on its activities. First, the Phase 3 clinical trial in Nash (non-alcoholic steatohepatitis) with “Resolve-It” fibrosis continues. Biotech awaits comments from the FDA, and their integration for the continuation of the study … file a New Drug Application (NDA) for elafibranor in Nash. Patient recruitments for a trial in the pediatric Nash and for the Phase 2 trial on the lipid composition of the liver were also suspended …

Electronic Health Records

Clinerion and Massive Bio partner to improve cancer patient lives | PRWeb | 12/3/2019

… offers Massive Bio access to oncology patient insights for site outreach and identification of cohorts for trial site selection and patient recruitment. Clinerion’s Patient Network Explorer queries anonymized patient data from its international network of … proprietary Big Data analytics technologies leverage real-time data from electronic health records which comply with international patient privacy and data security regulations. Clinerion is a global data technology service company headquartered in Switzerland. Clinerion’s …

Clinical Data

Outlook Therapeutics Receives FDA Agreement for Three Special Protocol Assessments for Additional Planned Clinical Trials of ONS-5010 | Globe Newswire | 12/3/2019

… in 2020. “We are very pleased to reach these agreements with the FDA so that we can continue to build clinical data for additional retinal indications beyond wet AMD for ONS-5010,” said Lawrence A … formulation of bevacizumab to treat retinal diseases.” Study initiation and patient recruitment for NORSE 4, 5 and 6 will begin after enrollment has been completed in the ongoing NORSE 2 clinical trial in wet AMD …

Clinical Trial Recruitment

Clinerion and Massive Bio partner to improve cancer patient lives | PRWeb | 12/3/2019

… offers Massive Bio access to oncology patient insights for site outreach and identification of cohorts for trial site selection and patient recruitment. Clinerion’s Patient Network Explorer queries anonymized patient data from its international network of … Patient Network Explorer radically improves the efficiency and effectiveness of clinical trial recruitment by offering data-driven protocol optimization, site feasibility evaluation and real-time patient search and identification to match patients to treatments. Our …

Patient Identification

Clinerion and Massive Bio partner to improve cancer patient lives | PRWeb | 12/3/2019

… offers Massive Bio access to oncology patient insights for site outreach and identification of cohorts for trial site selection and patient recruitment. Clinerion’s Patient Network Explorer queries anonymized patient data from its international network of … trials for patients treated at community practices. These services include patient identification/engagement, pre-screening, JIT site activation, and real-world data services. Massive Bio structures medical records, NGS results and clinical trials with its …

Patient Networks

Clinerion and Massive Bio partner to improve cancer patient lives | PRWeb | 12/3/2019

… better access for cancer patients to leading-edge clinical trials. BASEL, Switzerland Clinerion offers Massive Bio access to oncology patient insights for site outreach and identification of cohorts for trial site selection and patient recruitment. Clinerion’s Patient Network Explorer queries anonymized patient data from its international network of partner hospitals to deliver real-world health data insights useful for Massive Bio’s site outreach programs. Clinerion’s ANID technology meanwhile allows authorized …

Real World Evidence

Clinerion and Massive Bio partner to improve cancer patient lives | PRWeb | 12/3/2019

… better access for cancer patients to leading-edge clinical trials. BASEL, Switzerland Clinerion offers Massive Bio access to oncology patient insights for site outreach and identification of cohorts for trial site selection and patient recruitment. Clinerion’s Patient Network Explorer queries anonymized patient data from its international network of partner hospitals to deliver real-world health data insights useful for Massive Bio’s site outreach programs. Clinerion’s ANID technology meanwhile allows authorized …

Electronic Medical Record

Startup Deep 6 Lands $17 Million To Use AI To Help Find Patients For Clinical Trials | Forbes | 11/25/2019

Of the many inefficiencies throughout the long, expensive drug-discovery process , patient recruitment for clinical trials can be a particularly brutal bottleneck . For example, various studies have shown that as many as 40% of trials … a good match for a given trial is spread across electronic medical records (EMRs), physicians notes, pathology reports and other forms of documentation. Deep 6 uses natural language processing—an AI technique that allows software …

EMR

Startup Deep 6 Lands $17 Million To Use AI To Help Find Patients For Clinical Trials | Forbes | 11/25/2019

Of the many inefficiencies throughout the long, expensive drug-discovery process , patient recruitment for clinical trials can be a particularly brutal bottleneck . For example, various studies have shown that as many as 40% of trials … for a given trial is spread across electronic medical records (EMRs), physicians notes, pathology reports and other forms of documentation. Deep 6 uses natural language processing—an AI technique that allows software to “understand” language …

Medical Education

Medical Science Liaison - USA-HI-Honolulu | 11/23/2019

… and methods to mitigate adverse events. This includes real time patient case procedural training. As a subject matter expert, teach medical education and internal training courses. Provide product and disease-state educational/training support to … ongoing support. Identify key issues that are accelerating or inhibiting patient recruitment, quality data collection or patient retention. Recommend research sites that can perform well delivering patient enrollment and quality data. Support principal investigator and …

Patient Referrals

StudyKIK Introduces its New Clinical Trial Patient Recruitment Call Center Technology Platform, Increasing its Pre-screen Volume to Over 4,000 Patients Daily | 11/22/2019

patient recruitment and technology company that builds patient enrollment and communication solutions for clinical trials, has furthered its commitment to supporting research sites with the newest release of its Patient Qualification Suite technology platform. The “Patient Qualification Department” was created to support sites by reducing their workload, and increase the quality of patient referrals. StudyKIK’s site partners have long expressed the desire to place their full attention on patients that …

Patient Management

Care Partners Cancer Symptom Outcomes Study Now Enrolling Patients | PR Newswire | 11/21/2019

… Access to Single Fraction Radiation Therapy on Cancer Patients Enrolling in Hospice received Institutional Review Board (IRB) approval to initiate patient recruitment and is now enrolling. Single fraction radiation is widely available, but it is … staff has been trained and is ready to engage in patient management and data collection, overseen by our Medical Director Dr. Gerald Gibbs , a board-certified hematology/oncology specialist.” About Care Partners Care Partners offers …

Medicare

Care Partners Cancer Symptom Outcomes Study Now Enrolling Patients | PR Newswire | 11/21/2019

… Access to Single Fraction Radiation Therapy on Cancer Patients Enrolling in Hospice received Institutional Review Board (IRB) approval to initiate patient recruitment and is now enrolling. Single fraction radiation is widely available, but it is … been to provide “Exceptional Care, without Exception”. Care Partners is Medicare-certified and accredited by the Oregon Hospice & Palliative Care Association, and was chosen by their employees for the 7 th year as one of …

Mental Health

Arabkir Joint Medical Center & Institute of Child and Adolescent Health joins Patient Network Explorer, expanding Clinerion’s global hospital network to Armenia | PRWeb | 11/21/2019

… specialization, which includes services for allergology, dermatovenereology, pediatric gastroenterology and hepatology, pediatric rheumatology, trauma and orthopedics, endocrinology and diabetes, pulmonology, mental health, pediatric gynecology, and neurology and epileptology, among others. The hospital has departments for … in leading-edge, industry-sponsored trials and time savings in patient recruitment. We create innovative and disruptive fit-for-purpose solutions which enable pharmaceutical companies to shorten patient recruitment and save costs by streamlining operations …

Institutional Review Board

Care Partners Cancer Symptom Outcomes Study Now Enrolling Patients | PR Newswire | 11/21/2019

Institutional Review Board (IRB) approval to initiate patient recruitment and is now enrolling. Single fraction radiation is widely available, but it is not covered under the hospice benefit. People on hospice must temporarily revoke enrollment in order to be treated, which poses access challenges. This study will provide treatment and transportation funding for eligible cancer patients with bone metastases who are enrolled on Care Partners hospice service and elect to …

Patient Community

StudyKIK Introduces its New Clinical Trial Patient Recruitment Call Center Technology Platform, Increasing its Pre-screen Volume to Over 4,000 Patients Daily | PRWeb | 11/21/2019

StudyKIK Introduces its New Clinical Trial Patient Recruitment Call Center Technology Platform, Increasing its Pre-screen Volume to Over 4,000 Patients Daily Share Article The newest custom technology update to StudyKIK’s in-house Patient Qualification Department will allow StudyKIK to provide wider pre-screening support to research site partners, increasing clinical trial feasibility. These improvements have increased our agents’ efficiency by 90% and improved the quality of our pre-screening …

Sleep Apnea

fishbat Explains How to Overcome Clinical Trial Recruitment Challenges | PR Newswire | 11/21/2019

PRNewswire/ – Even with all the necessary tools for patient recruitment – qualified workforce, technological expertise, and overall knowledge of the industry – there are still a number of obstacles that can stand in one’s way. Despite how … disclosed include, but aren’t limited to, diabetes, asthma, arthritis, and sleep apnea. When screening and interviewing applicants, preexisting conditions should be discussed early in the process. This will help agencies determine the best candidates for …

TriNetX

TriNetX Signs Agreement with FDA Sentinel Program | PR Newswire | 7/14/2020

CAMBRIDGE, Mass. TriNetX, the global health research network that revolutionizes clinical research and enables discoveries through the generation of real-world evidence (RWE), today announced the signing of an agreement with the FDA Sentinel Program … art analytics to optimize protocol design and feasibility, site selection, patient recruitment, and enable discoveries through the generation of real-world evidence. The TriNetX platform is HIPAA and GDPR compliant. For more information, visit TriNetX

Pfizer

Craig Lipset Joins Transparency Life Science Advisory Board | Business & Finance | manchestertimes.com | Business Wire | 7/13/2020

… has spent more than a decade driving innovations in patient engagement strategies for clinical trials and previously led efforts for Pfizer to ensure every trial has patient involvement in the design stages. Lipset’s primary involvement … and clinical practice, which can help expedite both investigator and patient recruitment, resulting in fewer patients failing to complete a study and enhanced data quality. The technology, once implemented, can also help understand patient behavior …

Clinerion

DCC Ascendent Joins Clinerion’s Patient Network Explorer Platform and Improves Access to Leading-Edge Healthcare Treatment Options for Patients and Physicians in Bulgaria | PRWeb | 7/9/2020

DCC Ascendent Joins Clinerion’s Patient Network Explorer Platform and Improves Access to Leading-Edge Healthcare Treatment Options for Patients and Physicians in Bulgaria Share Article By joining the international hospital network on Clinerion’s Patient Network … in leading-edge, industry-sponsored trials and time savings in patient recruitment. Researchers gain access to real-time, longitudinal patient data from electronic health records for analysis. We enable pharmaceutical companies, CROs and SMOs to …

Genentech

Affimed Reports First Quarter 2020 Financial Results and Operational Progress | Globe Newswire | 6/23/2020

June 23, 2020 06:30 ET Source: Affimed N.V. AFM24: Affimed successfully completed the first dose cohort of its first-in-human phase 1/2A Study; Cohort 2 is open for patient recruitment Data on Affimed’s AFM24 (EGFR/CD16A) and Genentech’s RO7297089 (BCMA/CD16A) was presented at AACR Virtual Meeting II, showing potent killing of tumor cell lines and a good safety profile in the relevant pre-clinical models AFM13: Continued progress …

Parexel

Parexel and TriNetX Partner to Advance Real-world Data Use in Clinical Development | Globe Newswire | 6/18/2020

… with their mutual partner, Datavant, the alliance seeks to address barriers to RWD interoperability June 18, 2020 08:00 ET Source: Parexel International LLC BOSTON and DURHAM, N.C., and CAMBRIDGE, Mass., June 18, Parexel and TriNetX … art analytics to optimize protocol design and feasibility, site selection, patient recruitment, and enable discoveries through the generation of real-world evidence. The TriNetX platform is HIPAA and GDPR compliant. For more information, visit TriNetX …

Novartis

TrialSpark announces launch of Project Covalence, a clinical trial platform to rapidly test drugs and diagnostics for COVID-19 | PR Newswire | 6/16/2020

… tech entrepreneur Sam Altman , CEO of OpenAI, physician-scientist Dr. Mark C. Fishman , Harvard professor and Founding President of the Novartis Institutes for Biomedical Research, and TrialSpark. As researchers across industry and academia race to … home testing and specimen collection, protocol design and writing, digital patient recruitment, and other needs during this unique time. Project Covalence will also facilitate the creation of master protocols to enable shared control arms and …

Bristol-Myers

Medical Science Manager - Oncology - Bristol-Myers Squibb - Eigenbrakel | PR Newswire | 6/13/2020

Read what people are saying about working here. Bristol-Myers Squibb is a global Biopharma company committed to a single mission: to discover, develop, and deliver innovative medicines focused on helping millions of patients around … e.g. identification and assessment of potential study sites) to support patient recruitment and/or discussions around the safe and effective use of BMS investigational products, as agreed with local medical management and as defined by …

Bristol-Myers Squibb

Medical Science Manager - Oncology - Bristol-Myers Squibb - Eigenbrakel | PR Newswire | 6/13/2020

Read what people are saying about working here. Bristol-Myers Squibb is a global Biopharma company committed to a single mission: to discover, develop, and deliver innovative medicines focused on helping millions of patients around … e.g. identification and assessment of potential study sites) to support patient recruitment and/or discussions around the safe and effective use of BMS investigational products, as agreed with local medical management and as defined by …

Gilead Sciences

FiercePharmaAsia—Gilead’s nixed remdesivir trials; Indian pharmas’ site nods; CanSino’s COVID-19 vaccine | FiercePharma | 4/17/2020

FiercePharmaAsia—Gilead’s nixed remdesivir trials; Indian pharmas’ site nods; CanSino’s COVID-19 vaccine by Apr 17, 2020 10:48am Gilead Sciences, Lupin, Dr. Reddy’s, Biocon and CanSino made our news this week. (Google) With the coronavirus … spread of the novel coronavirus, Singapore’s Aslan Pharma has halted patient recruitment to an atopic dermatitis clinical trial of ASLAN004, an anti-IL-13Rα1 antibody it licensed from CSL that could challenge Sanofi and Regeneron’s …

Gilead

FiercePharmaAsia—Gilead’s nixed remdesivir trials; Indian pharmas’ site nods; CanSino’s COVID-19 vaccine | FiercePharma | 4/17/2020

FiercePharmaAsia—Gilead’s nixed remdesivir trials; Indian pharmas’ site nods; CanSino’s COVID-19 vaccine by Apr 17, 2020 10:48am Gilead Sciences, Lupin, Dr. Reddy’s, Biocon and CanSino made our news this week. (Google) With the coronavirus … spread of the novel coronavirus, Singapore’s Aslan Pharma has halted patient recruitment to an atopic dermatitis clinical trial of ASLAN004, an anti-IL-13Rα1 antibody it licensed from CSL that could challenge Sanofi and Regeneron’s …

Komodo Health

Komodo Health Teams Up with Karyopharm Therapeutics to Accelerate New Global Clinical Trial to Treat Patients with COVID-19 | Business Wire | 4/8/2020

SAN FRANCISCO- Komodo Health today announced a collaboration with Karyopharm Therapeutics Inc. (Nasdaq: KPTI) to accelerate clinical trial recruitment and site identification in an effort to speed patient access to a potential new treatment for … To optimize successful clinical trial site identification, physician engagement, and patient recruitment as soon as the trial launches, Karyopharm needed support to identify hundreds of providers and institutions with the highest at-risk populations to …

Novo Nordisk

Coronavirus tracker: U.K. plans major COVID-19 trial; Healthcare workers first up for J&J vaccine | FiercePharma | 4/3/2020

… technology can help speed the process. Eli Lilly and Bristol Myers Squibb have unveiled new patient access programs, and now Novo Nordisk has started a free 90-day insulin program for people who’ve lost insurance … of chloroquine might cause serious heart problems. The investigators halted patient recruitment to that arm after observing an abnormally high rate of heart arrhythmias and suggested that particular dosing strength “should not be recommended for …

AstraZeneca

BRILINTA reduced bleeding vs dual therapy in high-risk coronary patients in sub-analyses from Phase IV TWILIGHT trial | Business & Finance | manchestertimes.com | Business Wire | 3/30/2020

WILMINGTON, Del.–(BUSINESS WIRE)–Mar 30, 2020– Results from two subgroup analyses of the Phase IV independent TWILIGHT trial funded by AstraZeneca showed BRILINTA (ticagrelor) monotherapy reduced the risk of clinically relevant bleeding over 12 months compared to aspirin plus BRILINTA in high-risk coronary patients. One subgroup analysis (TWILIGHT-DM) included patients with diabetes who had undergone a successful percutaneous coronary intervention (PCI), a procedure to open a blocked …

Protalix

Protalix BioTherapeutics Announces Closing of $43.7 Million Private Placement | PR Newswire | 3/18/2020

CARMIEL, Israel , March 18, Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein … accelerated approval of PRX-102; slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; inability to monitor patients adequately during or after treatment; and …

Abeona Therapeutics

Clinical Trial Report Week 20th-24th January 2020: Seventeen Companies Reported Headline Results in Advancing their Candidate Product through Clinical Trials - ResearchAndMarkets.com | Business Wire | 3/9/2020

… trial, the drug candidate name or code, clinical indication, status of the study investigation in terms of study design and patient recruitment and any other significant comment(s) about the clinical study. The purpose of … Key Topics Covered: Introduction Table of Findings Disclaimer Companies Mentioned Abeona Therapeutics Akcea Therapeutics Akero Therapeutics BioTheryX Cellectis Cerevel Therapeutics Clover Biopharmaceuticals ContraFect Hutchison China MediTech Innovation Ionis Pharmaceuticals Neuroptika Pharmaceuticals Retrotope Tmunity Tolero Pharmaceuticals …

Massive Bio

Clinerion and Massive Bio partner to improve cancer patient lives | PRWeb | 12/3/2019

Clinerion and Massive Bio partner to improve cancer patient lives Share Article Clinerion, provider of the Patient Network Explorer platform which harnesses patient data from a global hospital network, and Massive Bio, provider of end … outreach and identification of cohorts for trial site selection and patient recruitment. Clinerion’s Patient Network Explorer queries anonymized patient data from its international network of partner hospitals to deliver real-world health data insights useful …

IQVIA

Abivax Receives French Regulatory Authority (ANSM) Approval to Include French Study Sites in its Phase 2b Ulcerative Colitis Clinical Trial and Provides a Progress Update of the ABX464 Clinical Development Plan in other Inflammatory Diseases | Business Wire | 11/21/2019

… Patient recruitment for this trial, which is conducted in cooperation with IQVIA, started in August and is proceeding according to plan. Top-line data from the induction study are expected by the end of 2020. ABX464 in Rheumatoid Arthritis In August 2019, the first patient was dosed in study ABX464-301 ( link to ClinicalTrial.gov ), a Phase 2a clinical trial of ABX464 to treat moderate to severe active rheumatoid arthritis (RA). The …

LifeSci Advisors

Abivax Receives French Regulatory Authority (ANSM) Approval to Include French Study Sites in its Phase 2b Ulcerative Colitis Clinical Trial and Provides a Progress Update of the ABX464 Clinical Development Plan in other Inflammatory Diseases | Business Wire | 11/21/2019

… in modified Mayo Score at 8 weeks, and secondary endpoints will include clinical remission, endoscopic improvement and biomarker fecal calprotectin. Patient recruitment for this trial, which is conducted in cooperation with IQVIA, started in August … Courteille [email protected] +33 6 85 34 24 04 Investors LifeSci Advisors Chris Maggos [email protected] +41 79 367 6254 Press Relations and Investors Europe MC Services AG Anne Hennecke [email protected] +49 211 …

Medidata

Medidata NEXT NYC 2019 Delivers Roadmap for Future Innovation in Clinical Research | 11/14/2019

Blog This Medidata , a global leader in creating end-to-end solutions that support the entire clinical trial process, and part of Dassault Systèmes, concluded its most successful NEXT NYC event to date. The two … trials through real-world evidence to improve trial design and patient recruitment, and use real-world evidence to bolster go-to-market strategies “We live in an age where healthcare is increasingly transformed by digital …

Intrexon

Intrexon Reports Third Quarter 2019 Financial Results | PR Newswire | 11/12/2019

GERMANTOWN, Md. Intrexon Corporation (NASDAQ: XON ), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced its third quarter financial results for 2019 … diabetes. ActoBio’s collaboration partner Oragenics, Inc. (NYSE American: OGEN) continues patient recruitment in the Phase 2 trial of AG013 for the treatment of severe oral mucositis and anticipates completion of enrollment by the end of …

PTC Therapeutics

Intrexon Reports Third Quarter 2019 Financial Results | PR Newswire | 11/12/2019

patient recruitment in the Phase 2 trial of AG013 for the treatment of severe oral mucositis and anticipates completion of enrollment by the end of the fourth quarter 2019; Exemplar Genetics, a wholly owned subsidiary of Intrexon, formed a collaboration with Lovelace Biomedical to continue development of Exemplar’s porcine animal model for sickle cell disease with support from the National Center for Advancing Translational Sciences; Collaborator PTC Therapeutics, Inc. (NASDAQ …

Boehringer Ingelheim

Saniona completes patient recruitment in Phase 2a hypothalamic obesity study Stockholm Stock Exchange:SANION | Globe Newswire | 11/11/2019

… indications such as Prader-Willi syndrome and hypothalamic obesity on its own. The research is focused on ion channels and the company has a broad portfolio of research programs. Saniona has partnerships with Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V and Cadent Therapeutics. Saniona is based in Copenhagen, Denmark, and the company’s shares are listed at Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com . About Hypothalamic Obesity …

Amgen

Ligand Pharmaceuticals Incorporated (LGND) CEO John Higgins on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/6/2019

… this year full-year sales are on track to exceed that by a good margin. We don’t market the drug. Amgen and Onyx do, but we book a royalty on worldwide sales. As we study … Novan has been making great progress as well. They completed patient recruitment in the e B-SIMPLE Phase 3 pivotal trials with SB206 for the treatment of molluscum contagiosum. Novan affirmed that topline data from …

Geron Corporation

Geron Corporation Reports Third Quarter 2019 Financial Results and Recent Events | Globe Newswire | 11/6/2019

November 06, 2019 16:10 ET Source: Geron Corporation MENLO PARK, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) – Geron Corporation (Nasdaq: GERN) today reported financial results for the third quarter and year-to-date as of September … IMerge Phase 3 trial, and we are currently focused on patient recruitment and enrollment. Another priority is to prepare for an End of Phase 2 meeting with the FDA to discuss potential late-stage development …

GlaxoSmithKline

Valneva Raises Product Sales Guidance Following Strong Nine-Month Results and R&D Execution Paris Stock Exchange:VLA | Globe Newswire | 10/31/2019

GlaxoSmithKline (GSK) Strategic Alliance Agreement (SAA) 1 . Excluding this GSK SAA termination effect, expected overall revenues would be between €135 million - €140 million The Company also confirms expected EBITDA, in line with its previous guidance, of €5 million to €10 million in 2019. Excluding the GSK SAA termination effects, EBITDA would be €15m - €20m Two significant R&D milestones reported in the third quarter Completion of Phase 2 patient recruitment

Genstar Capital

Signant Health Names Roger Smith CEO | PR Newswire | 7/8/2020

… services to support more than 4,000 global clinical trials across an array of therapeutic areas. Signant Health was created by Genstar Capital in 2018 through the merger of Bracket Global and CRF Health, two leaders … working closely with research sites and pharmaceutical organizations to solve patient recruitment challenges by utilizing digital technology and data science. Prior to joining PPD in 2013 through its acquisition of Acurian, Mr. Smith held a …

Advarra Announces Appointment of Gadi Saarony as Chief Executive Officer | PR Newswire | 4/15/2020

… Services Officer, responsible for the operational delivery of its clinical research services. His global remit included site strategy and selection, patient recruitment, data management, biostatistics and programming, clinical operations, project management and resourcing, Phase I … pursuit of advancing human health.” David Golde , Managing Director of Genstar Capital and Advarra Chairman of the Board, said, “Gadi brings extensive strategic, commercial, and operational leadership in the pharmaceutical services industry and we are …

William Blair

Audentes Therapeutics, Inc. (BOLD) CEO Matt Patterson on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/11/2019

… Conference Call Participants Dae Gon - SVB Leerink Chris Raymond - Piper Jaffray Anupam Rama - JPMorgan Steve Seedhouse - Raymond James Rajiv Prasad - William Blair Matthew Luchini - BMO Capital Market Operator Good afternoon ladies and gentlemen and welcome … be in a very good competitive position in terms of patient recruitment. You know, it’s similar to what we’re seeing in Pompe. As we’re going out and talking with potential investigators about our approach and …

Minerva Neurosciences Inc (NERV) Q3 2019 Earnings Call Transcript | The Motley Fool | 11/4/2019

… patient enrollment in our pivotal Phase III trial with our lead product roluperidone and we have resumed the pacing of patient recruitment following the temporary delay we discussed in October. Beginning with Phase III trial … Thank you. Our next question is from Myles Minter from William Blair. Your line is now open. Myles Minter – William Blair – Analyst Hi guys. Thanks for taking the questions. I’m just wondering about the proportion …

Goldman Sachs

Radius Health, Inc. (RDUS) CEO Jesper Høiland on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/6/2019

… Morris - Chief Medical Officer Pepe Carmona - Senior Vice President & Chief Financial Officer Conference Call Participants Jessica Fye - JPMorgan Paul Choi - Goldman Sachs Connor Meehan - Morgan Stanley CJ Zopf - Cowen Eun Yang - Jefferies Operator Good afternoon … patients recruited to date is tracking closely to that percentage. Patient recruitment is ongoing and we continue to target completion of recruitment in the third quarter of 2020. The Phase 3 WearABLe Study for the …

Atara Biotherapeutics, Inc. (ATRA) CEO Isaac Ciechanover on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/12/2019

… Financial Officer Conference Call Participants Anupam Rama - JPMorgan John Newman - Canaccord Salim Syed - Mizuho Matt Phipps - William Blair Maryana Breitman - Goldman Sachs Marc Frahm - Cowen and Company Maury Raycroft - Jefferies Operator Good morning, ladies and … ultrarare and rapidly progressive diseases. For example, the window for patient recruitment during the course of disease progression is short and the overall incidence of the disease requires a substantial number of study sites. As …

Morgan Stanley

Radius Health, Inc. (RDUS) CEO Jesper Høiland on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/6/2019

… Pepe Carmona - Senior Vice President & Chief Financial Officer Conference Call Participants Jessica Fye - JPMorgan Paul Choi - Goldman Sachs Connor Meehan - Morgan Stanley CJ Zopf - Cowen Eun Yang - Jefferies Operator Good afternoon everyone and welcome to … patients recruited to date is tracking closely to that percentage. Patient recruitment is ongoing and we continue to target completion of recruitment in the third quarter of 2020. The Phase 3 WearABLe Study for the …

Laboratory Corporation of America Holdings (LH) CEO David King on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 10/24/2019

… Coldwell - Baird Donald Hooker - KeyBanc Mark Massaro - Canaccord Matt Larew - William Blair Derik De Bruin - Bank of America Ricky Goldwasser - Morgan Stanley Operator Ladies and gentlemen, thank you for standing by. And welcome to the … value of the data. They’ve seen the value of the patient recruitment strategy through the voice of the customer and the specific inclusion and exclusion criteria that they can manage, trials in a much quicker …

Merrill Lynch

Ascendis Pharma A/S Announces Three Investor Presentations in September Nasdaq:ASND | Globe Newswire | 8/30/2019

… Global Healthcare Conference Location New York Date Tuesday, September 10, 2019 Time 2:55 p.m. Eastern Time Event Bank of America Merrill Lynch Global Healthcare Conference 2019 Location London Date Thursday, September 19, 2019 Time 10:40 … other development programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; dependence on third party manufacturers to supply study drug for planned clinical studies; and our ability to obtain additional …

Ascendis Pharma A/S Announces Three Investor Presentations in September | Markets Insider | Business Insider | 8/29/2019

… Global Healthcare Conference Location New York Date Tuesday, September 10, 2019 Time 2:55 p.m. Eastern Time Event Bank of America Merrill Lynch Global Healthcare Conference 2019 Location London Date Thursday, September 19, 2019 Time 10:40 … other development programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; dependence on third party manufacturers to supply study drug for planned clinical studies; and our ability to obtain additional …

Windham Venture Partners

SubjectWell Raises $10M to Expand Risk-Free Clinical Trials Marketplace for Patient Recruitment | HIT Consultant | 6/19/2019

Patient Recruitment and is located at https://hitconsultant.net/2019/06/19/subjectwell-risk-free-clinical-trials-marketplace-funding/. Captcha SubjectWell , an Austin, TX-based risk-free clinical trials marketplace for patient recruitment has raised $10 million in Series A funding led by Windham Venture Partners, with participation from previous investors Healthy Ventures and Geekdom Fund. SubjectWell Clinical Trials Marketplace Founded in 2012, SubjectWell is increasing participation in clinical research by providing a …

SubjectWell Raises $10M to Expand Its Risk-Free Patient Recruitment Marketplace | Business Wire | 6/18/2019

SubjectWell Raises $10M to Expand Its Risk-Free Patient Recruitment Marketplace 18 hrs ago Save AUSTIN, Texas–(BUSINESS WIRE)–Jun 18, 2019– SubjectWell , the risk-free clinical trials marketplace for patient recruitment, announced today its $10 million in Series A funding led by Windham Venture Partners , with participation from previous investors Healthy Ventures and Geekdom Fund . This funding bolsters SubjectWell’s mission of building awareness of and increasing participation in clinical …

RBC Capital Markets

ObsEva SA (OBSV) CEO Ernest Loumaye on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/14/2019

… Pierre Gotteland - Chief Scientific Officer Wim Souverijns - Chief Commercial Officer Tim Adams - Chief Financial Officer Conference Call Participants Justin Burns - RBC Capital Markets Sheldon Fan - SVB Leerink Mark Connolly - Credit Suisse Liana Moussatos - Wedbush Securities … is a U.S. only trial and we continue to expect patient recruitment to be completed this quarter. We continue to anticipate announcing 6 months primary endpoint results from PRIMROSE 1 in the fourth quarter of …

Arena Pharmaceuticals, Inc. (ARNA) CEO Amit Munshi on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/10/2019

… Officer Amit Munshi - President & Chief Executive Officer Preston Klassen - Chief Medical Officer . Conference Call Participants Jessica Fye - JPMorgan Kennen MacKay - RBC Capital Markets Joel Beatty - Citi Dae Gon - SVB Leerink Alan Carr - Needham Shanshan Xu … decisions and discussions; timing of preclinical and clinical trials and patient recruitment for clinical trials, which is competitive and challenging and may take longer than we project; preclinical and clinical data related to drugs and …

Citigroup

Iveric Bio, Inc. (ISEE) CEO Glenn Sblendorio on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/12/2019

… Rezaei - SVP & Chief Medical Officer David Carroll - SVP, CFO & Treasurer Conference Call Participants Matthew Bannon - JPMorgan Chase & Co. Samantha Semenkow - Citigroup Operator Good day, and welcome to the IVERIC bio’s First Quarter 2019 Results Conference … fourth quarter of this year, 2019. In February, we completed patient recruitment for our Phase IIb randomized, double-masked, sham-controlled clinical trial assessing the safety and efficacy of Zimura monotherapy in patients with autosomal …

Arena Pharmaceuticals Inc (ARNA) Q1 2019 Earnings Call Transcript - Nasdaq.com | 5/10/2019

… and include risks related to timing and outcomes of regulatory decisions and discussion, timing of preclinical and clinical trials and patient recruitment for clinical trials, which is competitive and challenging and may take longer than … Beatty with Citi. Your line is now open. Joel Beatty – Citigroup – Analyst Hi. Thanks for the questions. So if you could give color on the potential at this point for any first-dose monitoring for …

SunTrust Robinson Humphrey

Nuvectra Corporation (NVTR) CEO Fred Parks on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/5/2019

… and Chief Financial Officer Paul Hanchin - President Conference Call Participants Dave Turkaly - JMP Securities Matt Wizman - Raymond James Bruce Nudell - SunTrust Robinson Humphrey Operator Good day, ladies and gentlemen, and welcome to the Q1 2019 … we work with marketing to initialize – utilize social media in patient recruitment. As we look ahead, we expect to add additional study on the design to highlight the efficacy profile of the different stimulation modes …

Nuvectra Corporation Common Stock (NVTR) Q1 2019 Earnings Call Transcript | Yahoo News | 5/2/2019

… Enrollment should be completed by September of this year, as we work with marketing to initialize – utilize social media in patient recruitment. As we look ahead, we expect to add additional study on the design … Bruce Nudell from SunTrust. Your line is open. Bruce Nudell – SunTrust Robinson Humphrey – Analyst Hi. Thanks for taking the question. Fred, over the last two quarters, the SCS market as others have mentioned has slowed …

University Hospital

Ege University improves patient access to leading-edge healthcare treatment options by joining Clinerion’s Patient Network Explorer platform | PRWeb | 7/2/2020

… edge treatments and medications by joining the international hospital network on Clinerion’s Patient Network Explorer platform. On the platform, the university hospital’s patients are brought to the attention of researchers and trial sponsors who are … in leading-edge, industry-sponsored trials and time savings in patient recruitment. Researchers gain access to real-time, longitudinal patient data from electronic health records for analysis. We enable pharmaceutical companies, CROs and SMOs to …

Japan curbed COVID-19 spread, facing patient shortage for clinical trials - Business Insider | 6/24/2020

… take some time before clinical research is completed,” said Tetsuya Nakamura, who is running a trial of Avigan at Gunma University Hospital in central Japan. With a dearth of domestic patients, Japan may have to … been launched in Japan, but most are still in the patient recruitment phase, according to trials' tracking data. Interest in Avigan, known generically as favipiravir, soared in March after a Chinese official said it …

MD Anderson Cancer Center

Affimed Reports First Quarter 2020 Financial Results and Operational Progress | Globe Newswire | 6/23/2020

patient recruitment Data on Affimed’s AFM24 (EGFR/CD16A) and Genentech’s RO7297089 (BCMA/CD16A) was presented at AACR Virtual Meeting II, showing potent killing of tumor cell lines and a good safety profile in the relevant pre-clinical models AFM13: Continued progress on the REDIRECT monotherapy study in pTCL as well as on the AFM13 combination with cbNk investigator sponsored study at MD Anderson Cancer Center in CD30-positive T cell …

Affimed Reports First Quarter 2020 Financial Results and Operational Progress Nasdaq:AFMD | Globe Newswire | 6/23/2020

patient recruitment Data on Affimed’s AFM24 (EGFR/CD16A) and Genentech’s RO7297089 (BCMA/CD16A) was presented at AACR Virtual Meeting II, showing potent killing of tumor cell lines and a good safety profile in the relevant pre-clinical models AFM13: Continued progress on the REDIRECT monotherapy study in pTCL as well as on the AFM13 combination with cbNk investigator sponsored study at MD Anderson Cancer Center in CD30-positive T cell …

Medical Center

Is faster better? A randomised crossover study comparing algorithms for closed-loop automatic oxygen control | BMJ | 6/19/2020

… Clinical Studies , University Children’s Hospital , Tuebingen , Germany 4 Division of Paediatric Epidemiology, Institute of Medical Biostatistics, Epidemiology and Informatics , University Medical Center Mainz , Mainz , Germany Correspondence to Dr Christoph E Schwarz, Neonatology, University of Tuebingen … CES and AK contributed equally. Contributors CES coordinated and supervised patient recruitment and data collection at the study centres, evaluated the analyses and drafted the initial and the revised manuscript; AK conducted patient recruitment and …

Randomised, non-inferiority, controlled procedural outcomes TrIal comParing reverse T And Protrusion versus double-kissing and crush stenting: protocol of the TIP TAP I randomised trial | BMJ | 6/17/2020

… and mean lumen area. Analysis of OCT data OCT data are analysed offline using QCU-CMS V.4-69 (Leiden University Medical Center in cooperation with MEDIS, Leiden). Stented segments each with 0.5 mm through the … and is considered a screening failure. Selection and withdrawal Recruitment Patient recruitment is performed within the patients treated at the Kardiologie I of the Universitätsmedizin Mainz. Patients planned (based on clinical indication and current guidelines …

University Medical Center

Is faster better? A randomised crossover study comparing algorithms for closed-loop automatic oxygen control | BMJ | 6/19/2020

… Paediatric Clinical Studies , University Children’s Hospital , Tuebingen , Germany 4 Division of Paediatric Epidemiology, Institute of Medical Biostatistics, Epidemiology and Informatics , University Medical Center Mainz , Mainz , Germany Correspondence to Dr Christoph E Schwarz, Neonatology, University of … CES and AK contributed equally. Contributors CES coordinated and supervised patient recruitment and data collection at the study centres, evaluated the analyses and drafted the initial and the revised manuscript; AK conducted patient recruitment and …

Randomised, non-inferiority, controlled procedural outcomes TrIal comParing reverse T And Protrusion versus double-kissing and crush stenting: protocol of the TIP TAP I randomised trial | BMJ | 6/17/2020

… minimum and mean lumen area. Analysis of OCT data OCT data are analysed offline using QCU-CMS V.4-69 (Leiden University Medical Center in cooperation with MEDIS, Leiden). Stented segments each with 0.5 mm through … and is considered a screening failure. Selection and withdrawal Recruitment Patient recruitment is performed within the patients treated at the Kardiologie I of the Universitätsmedizin Mainz. Patients planned (based on clinical indication and current guidelines …

Mayo Clinic

Basilea reports positive preclinical data on oncology drug candidates derazantinib and lisavanbulin at AACR-NCI-EORTC conference Swiss Stock Exchange:BSLN | Globe Newswire | 10/30/2019

… study in patients with advanced urothelial cancer. 1 A second abstract presented data obtained in collaboration with Dr. Jann Sarkaria (Mayo Clinic, Rochester), demonstrating significant survival benefits in patient-derived glioblastoma models after treatment with … to chemotherapy with the standard-of-care drug temozolomide. 4 Patient recruitment into a further phase 1 study in recurrent glioblastoma or high-grade glioma with the oral formulation has just been completed with the …

Basilea reports positive preclinical data on oncology drug candidates derazantinib and lisavanbulin at AACR-NCI-EORTC conference | The Wapakoneta Daily News | 10/30/2019

… study in patients with advanced urothelial cancer. 1 A second abstract presented data obtained in collaboration with Dr. Jann Sarkaria (Mayo Clinic, Rochester), demonstrating significant survival benefits in patient-derived glioblastoma models after treatment with … to chemotherapy with the standard-of-care drug temozolomide. 4 Patient recruitment into a further phase 1 study in recurrent glioblastoma or high-grade glioma with the oral formulation has just been completed with the …

Catholic Health Services

Will New Alliances Aid Quest Diagnostics (DGX) Q3 Earnings? - October 17, 2019 - Zacks.com | 10/17/2019

… this strategy quite successfully. The company’s top-line number is expected to reflect the impact of its recent partnerships with Catholic Health Services (CHS), an integrated health care delivery system, and hc1, a bioinformatics player … regard, the company recently launched Quest Clinical Trial Connect, a patient recruitment service. Apart from these five elements, in terms of Quest Diagnostics’ efforts to ramp up its operating efficiency, it endeavors to scale up …

Will New Alliances Aid Quest Diagnostics (DGX) Q3 Earnings? | Yahoo News | 10/17/2019

… this strategy quite successfully. The company’s top-line number is expected to reflect the impact of its recent partnerships with Catholic Health Services (CHS), an integrated health care delivery system, and hc1, a bioinformatics player … regard, the company recently launched Quest Clinical Trial Connect, a patient recruitment service. Apart from these five elements, in terms of Quest Diagnostics’ efforts to ramp up its operating efficiency, it endeavors to scale up …

Catholic Health

Will New Alliances Aid Quest Diagnostics (DGX) Q3 Earnings? - October 17, 2019 - Zacks.com | 10/17/2019

… this strategy quite successfully. The company’s top-line number is expected to reflect the impact of its recent partnerships with Catholic Health Services (CHS), an integrated health care delivery system, and hc1, a bioinformatics player … regard, the company recently launched Quest Clinical Trial Connect, a patient recruitment service. Apart from these five elements, in terms of Quest Diagnostics’ efforts to ramp up its operating efficiency, it endeavors to scale up …

Will New Alliances Aid Quest Diagnostics (DGX) Q3 Earnings? | Yahoo News | 10/17/2019

… this strategy quite successfully. The company’s top-line number is expected to reflect the impact of its recent partnerships with Catholic Health Services (CHS), an integrated health care delivery system, and hc1, a bioinformatics player … regard, the company recently launched Quest Clinical Trial Connect, a patient recruitment service. Apart from these five elements, in terms of Quest Diagnostics’ efforts to ramp up its operating efficiency, it endeavors to scale up …

University of Texas System

Positive Developments From Clinical Studies and FDA Approvals Pushing Biotech Stocks to New Highs | PR Newswire | 10/18/2017

… company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that … trial, as it should help improve our chances for timely patient recruitment. In addition, seven of these interested sites are in Poland where we believe we will have access to a higher percentage of patients …

Positive Developments From Clinical Studies and FDA Approvals Pushing Biotech Stocks to New Highs | PR Newswire | 10/18/2017

… company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that … trial, as it should help improve our chances for timely patient recruitment. In addition, seven of these interested sites are in Poland where we believe we will have access to a higher percentage of patients …

Aetna

Patient co-creation is a tall, but worthwhile, order for health innovators | MobiHealthNews | 11/27/2019

… stakeholders along with you through your ideation and planning involving patients inthe design, co-creation, etc,” Kelly McKee, head of patient recruitment and patient-centric innovations at Vertex Pharmaceuticals, said. “When you bring along individuals … building,” said Carson Pickens, executive director of product management at Aetna. “To me there’s a big component around how you structure design organizations and engineering organizations in order to factor in this kind of feedback …

Radius Health Announces Third Quarter 2019 Results and Corporate Update | Globe Newswire | 11/6/2019

… TYMLOS achieved an average 50% NBRx share and its total market TRx share further increased to 40%. After decisions from Aetna, Cigna and others, 2020 Medicare Part D coverage for TYMLOS will increase from 67 … majority of sites open and activated. Radius expects to complete patient recruitment in the third quarter of 2020. Financial Highlights and Guidance In the third quarter of 2019, TYMLOS gross profit covered the Company’s selling …

UnitedHealthcare

Laboratory Corporation of America Holdings (LH) CEO David King on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 4/30/2019

… rest of the quarter. We also pleased that LabCorp and all of its specialty-branded laboratories were selected to be UnitedHealthcare preferred laboratory network providers. LabCorp’s selection reflects a long and deep partnership with United … 280 basis points. Our data capabilities, a critical asset for patient recruitment and site selection strategies are much copied but nowhere near equal. We are the industry leader in companion diagnostics and are now seeing …

Can Five Elements Drive Quest Diagnostics (DGX) Q1 Earnings? - April 17, 2019 - Zacks.com | 4/17/2019

… relationships with hospital health systems, Quest Diagnostics entered 2019 on a bullish note. Banking on its in-network status with UnitedHealthcare, Horizon Blue Cross Blue Shield of New Jersey and Blue Cross Blue Shield of … regard, the company recently launched Quest Clinical Trial Connect, a patient recruitment service. Apart from these five elements, in terms of the company’s efforts to ramp up operating efficiency, Quest Diagnostics’ Invigorate cost-cutting initiatives …

Per Norlen

Alligator Bioscience AB (publ) Interim Report January-June 2020 | PR Newswire | 7/13/2020

… value of the clinical drug candidates, while reducing preclinical expenses including a 20% reduction in workforce. The adjustments will extend Alligator’s cash runway into the fourth quarter of 2021. Effects of Covid-19 : Patient recruitment in the Phase I studies was temporarily paused in March and April 2020 due to the Covid-19 pandemic but has been resumed. Approved governmental subsidies amount to SEK 1.5 to 2.0 million. Financial summary …

Ian Rentsch

DCC Ascendent Joins Clinerion’s Patient Network Explorer Platform and Improves Access to Leading-Edge Healthcare Treatment Options for Patients and Physicians in Bulgaria | PRWeb | 7/9/2020

… well by other competent authorities. “We are thrilled to welcome DCC Ascendent and patients from Bulgaria into our fold,” says Ian Rentsch, CEO of Clinerion. “Clinerion is dedicated to bringing more and better treatment options … in leading-edge, industry-sponsored trials and time savings in patient recruitment. Researchers gain access to real-time, longitudinal patient data from electronic health records for analysis. We enable pharmaceutical companies, CROs and SMOs to …

Anupam Rama

Edited Transcript of INFI.OQ earnings conference call or presentation 11-May-20 8:30pm GMT | Yahoo News | 7/8/2020

… Chairman & CEO Jayne Kauffman Infinity Pharmaceuticals, Inc. - Senior Executive Coordinator Lawrence E. Bloch Infinity Pharmaceuticals, Inc. - President Conference Call Participants Anupam Rama JP Morgan Chase & Co, Research Division - VP and Analyst James William Birchenough Wells … insights can be generated to inform new site initiation and patient recruitment initiatives. Though COVID-19 has limited our access to sites over the past few months and made this work more challenging, we have …

David Gold

Advarra Announces Appointment of Gadi Saarony as Chief Executive Officer | PR Newswire | 4/15/2020

… Services Officer, responsible for the operational delivery of its clinical research services. His global remit included site strategy and selection, patient recruitment, data management, biostatistics and programming, clinical operations, project management and resourcing, Phase I … sites, and partners in the pursuit of advancing human health.” David Golde , Managing Director of Genstar Capital and Advarra Chairman of the Board, said, “Gadi brings extensive strategic, commercial, and operational leadership in the pharmaceutical …

Gadi Lachman

TriNetX Readies its Real-World Data Platform and Global Network of Healthcare Organizations to Support COVID-19 Clinical Research | PR Newswire | 3/24/2020

… 19 clinical trials and observational studies. “Accelerating research holds the key to stemming the tide of this insidious disease,” said Gadi Lachman , CEO of TriNetX. “To do that we must provide researchers with the tools … art analytics to optimize protocol design and feasibility, site selection, patient recruitment, and enable discoveries through the generation of real-world evidence. The TriNetX platform is HIPAA and GDPR compliant. For more information, visit TriNetX …

Laura Wood

Clinical Trial Report Week 20th-24th January 2020: Seventeen Companies Reported Headline Results in Advancing their Candidate Product through Clinical Trials - ResearchAndMarkets.com | Business Wire | 3/9/2020

… trial, the drug candidate name or code, clinical indication, status of the study investigation in terms of study design and patient recruitment and any other significant comment(s) about the clinical study. The purpose of … about this report visit https://www.researchandmarkets.com/r/qm49c5 Contacts ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call …

Glen de Vries

Medidata NEXT NYC 2019 Delivers Roadmap for Future Innovation in Clinical Research | 11/14/2019

… patient recruitment, and use real-world evidence to bolster go-to-market strategies “We live in an age where healthcare is increasingly transformed by digital technologies,” said Glen de Vries, co-CEO and co-founder, Medidata. “This year’s Medidata NEXT NYC took us further down the path to explore how we, as an industry, can fulfill the promise of ensuring the right therapy gets to the right patient at the …

Preston Klassen

Arena Pharmaceuticals Inc (ARNA) Q3 2019 Earnings Call Transcript | The Motley Fool | 11/11/2019

… quarter 2019 financial results. Joining me on today’s call is Amit Munshi, our President and Chief Executive Officer; and Dr. Preston Klassen, our Head of Research and Development. Before we begin, I’d like to remind … decisions and discussions; timing of preclinical and clinical trials, including patient recruitment for clinical trials, which is competitive and challenging and may take longer than we project; preclinical and clinical results and the timing of …

David Lawrence

Valneva SE (INRLF) CEO Thomas Lingelbach on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/3/2019

Valneva SE ( OTC:INRLF ) Q3 2019 Earnings 31, 2019 9: Thomas Lingelbach - CEO David Lawrence - CFO Samir Devani - Rx Securities Max Herrmann - Stifel Suzanne van Voorthuizen - Kempen & Co Securities Simon Scholes - First Berlin Equity Research … the world right now, we have been able to complete patient recruitment for the 2 Phase II studies on time and according to our plan. And hence, the product candidate remains fully on track towards …

David Law

Valneva SE (INRLF) CEO Thomas Lingelbach on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/3/2019

Valneva SE ( OTC:INRLF ) Q3 2019 Earnings 31, 2019 9: Thomas Lingelbach - CEO David Lawrence - CFO Samir Devani - Rx Securities Max Herrmann - Stifel Suzanne van Voorthuizen - Kempen & Co Securities Simon Scholes - First Berlin Equity Research … the world right now, we have been able to complete patient recruitment for the 2 Phase II studies on time and according to our plan. And hence, the product candidate remains fully on track towards …

Steve Cutler

Icon snaps up at-home patient services company | FierceBiotech | 10/29/2019

… patient recruitment, engagement and retention.” RELATED: Irish CRO Icon rolls out digital platform developed with Dimension Data Dr. Steve Cutler, Icon’s chief, added: “ICON has a focused patient, site and data strategy which is helping us to improve site identification, study placement, patient recruitment and retention. A core objective of our patient centered approach is to increase predictability in patient recruitment and improve patient engagement. “Symphony Clinical Research further enhances …

Wes Wheeler

Marken Launches New Marketing Campaign | PR Newswire | 10/24/2019

… include Marken’s home healthcare and cell & therapy services. Marken is now able to create customizable, study specific solutions for improved patient recruitment, retention, quality and cost efficiency. In the cell, gene, and immunotherapy space, the … best, full service clinical supply chain partner for our customers.” Wes Wheeler , Marken’s CEO added, “We continue to invest in new technology and services with the help of UPS and will pursue six-sigma quality …

Erin Wright

Laboratory Corporation of America Holdings (LH) CEO David King on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 10/24/2019

… Lisa Gill - JPMorgan Jack Meehan - Barclays Kevin Caliendo - UBS Kevin Ellich - Craig-Hallum Ralph Giacobbe - Citi Bill Quirk - Piper Jaffray Erin Wright - Credit Suisse Eric Coldwell - Baird Donald Hooker - KeyBanc Mark Massaro - Canaccord Matt Larew … value of the data. They’ve seen the value of the patient recruitment strategy through the voice of the customer and the specific inclusion and exclusion criteria that they can manage, trials in a much quicker …

Donald Hooker

Laboratory Corporation of America Holdings (LH) CEO David King on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 10/24/2019

… Caliendo - UBS Kevin Ellich - Craig-Hallum Ralph Giacobbe - Citi Bill Quirk - Piper Jaffray Erin Wright - Credit Suisse Eric Coldwell - Baird Donald Hooker - KeyBanc Mark Massaro - Canaccord Matt Larew - William Blair Derik De Bruin - Bank of … value of the data. They’ve seen the value of the patient recruitment strategy through the voice of the customer and the specific inclusion and exclusion criteria that they can manage, trials in a much quicker …

Bill Quirk

Laboratory Corporation of America Holdings (LH) CEO David King on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 10/24/2019

… Development Conference Call Participants Lisa Gill - JPMorgan Jack Meehan - Barclays Kevin Caliendo - UBS Kevin Ellich - Craig-Hallum Ralph Giacobbe - Citi Bill Quirk - Piper Jaffray Erin Wright - Credit Suisse Eric Coldwell - Baird Donald Hooker - KeyBanc Mark … value of the data. They’ve seen the value of the patient recruitment strategy through the voice of the customer and the specific inclusion and exclusion criteria that they can manage, trials in a much quicker …

Jakob Lindberg

Patient Recruitment in the Pivotal Phase 2-Study HORIZON Completed | PR Newswire | 9/26/2019

Jakob Lindberg , CEO of Oncopeptides. About the OP-106 HORIZON study Patient recruitment in the pivotal HORIZON study is now completed. The patients in the study are refractory to pomalidomide and/or daratumumab after failing on immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). The interim data presented at IMW 2019 was based on a data cut-off dated July 30, 2019 , with 136 patients treated. The goal is to present …

Paul G. Richardson

New Interim Data in RRMM Patients With Extramedullary Disease from the Pivotal Phase 2 Horizon-study Presented at International Myeloma Workshop | Markets Insider | Business Insider | 9/15/2019

… Massachusetts , USA. The data focused on patients with extramedullary disease (EMD) and was presented in an oral presentation by Professor Paul G. Richardson . Oncopeptides will host a conference call to review this data on Monday … 2019 at 14.30 (CET). About the OP-106 HORIZON study Patient recruitment in the HORIZON study is ongoing. The interim data presented at IMW 2019 is based on a data cut-off dated July 30 …

Alexis Peyroles

OSE Immunotherapeutics Reports First Half 2019 Results and Provides a Corporate Update | Markets Insider | Business Insider | 9/5/2019

… assets in multiple indications, clearly positioning OSE Immunotherapeutics as an emerging leader in the immuno-oncology and autoimmune spaces,” said Alexis Peyroles, chief executive officer of OSE Immunotherapeutics . Major clinical progress with four differentiated therapeutic … Phase 3 trial in NSCLC and recommended the continuation of patient recruitment, without any modifications. NSCLC is a large patient population with no currently approved therapeutic option, and with strong clinical need . The Japanese Patent …

James Johnson

VirTrial Wins MedTech Breakthrough Award for Drug Development Innovation and Three Gold Stevie® Awards in American Business Awards® | PRWeb | 6/13/2019

… vision for creating a hyper-efficient hybrid virtual trial model, but they have the data to back it up,” said James Johnson, managing director, MedTech Breakthrough. SCOTTSDALE, Ariz. VirTrial was recently awarded Best New Technology … text, and email offer convenience to patients that can speed patient recruitment, increase retention, and generate improved outcomes. Unlike other virtual trial offerings, VirTrial’s Patient Management Program is the only solution that operates on any …

Mark Hanley

VirTrial Wins MedTech Breakthrough Award for Drug Development Innovation and Three Gold Stevie® Awards in American Business Awards® | PRWeb | 6/13/2019

… recognized by the MedTech Breakthrough awards program and the American Business Awards and I congratulate all fellow award winners,” said Mark Hanley, CEO, VirTrial. “Our mission at VirTrial is to provide technology solutions that reduce … text, and email offer convenience to patients that can speed patient recruitment, increase retention, and generate improved outcomes. Unlike other virtual trial offerings, VirTrial’s Patient Management Program is the only solution that operates on any …

James Johns

VirTrial Wins MedTech Breakthrough Award for Drug Development Innovation and Three Gold Stevie® Awards in American Business Awards® | PRWeb | 6/13/2019

… vision for creating a hyper-efficient hybrid virtual trial model, but they have the data to back it up,” said James Johnson, managing director, MedTech Breakthrough. SCOTTSDALE, Ariz. VirTrial was recently awarded Best New Technology … text, and email offer convenience to patients that can speed patient recruitment, increase retention, and generate improved outcomes. Unlike other virtual trial offerings, VirTrial’s Patient Management Program is the only solution that operates on any …

Walter Klemp

US Biopharma Company Undertakes Anti-Cancer Clinical Trials in Poland, First Patient Showing Positive Initial Treatment | PR Newswire | 4/29/2019

… promising anti-cancer drugs in the pipeline is augmenting US clinical trials with trials in Poland , speeding the process of patient recruitment and data collection. The company, Moleculin (NASDAQ: MBRX ), recently recruited 3 patients in … for many patients suffering from hard-to-combat cancers,” said Walter Klemp , CEO, Moleculin Inc. “For a smaller pharmaceutical company with a promising roster of drug candidates for targeting these highly resistant tumors, speed in …

David Herr

Bioclinica Launches NAFLD/NASH Clinical Trials Practice | PRWeb | 4/18/2019

… NAFLD and NASH trials to accelerate clinical development of effective treatments approved by international regulators,” said Bioclinica President and CEO David Herron. “Developing NAFLD and NASH therapeutics requires innovation in patient screening and monitoring in … CROs), Bioclinica offers a global network of research sites and patient recruitment services to provide committed, detail-focused service through all stages of drug development. The company’s thousands of employees serve more than 400 pharmaceutical …

Ken Wallace

Patient Advertising Guru Continues to “Rock Enroll” by Adding a Real-Life Patient Recruitment Guru to The Team | PR Newswire | 1/2/2018

Patient Advertising Guru Continues to “Rock Enroll” by Adding a Real-Life Patient Recruitment Guru to The Team Patient Recruitment Industry Veteran Ken Wallace, MBA, joins Patient Advertising Guru as Vice (Guru) President News provided by 08:40 ET Share this article PLAINVIEW, N.Y. Patient Advertising Guru , an advertising firm primarily focused on patient recruitment for clinical trials, announced that Ken Wallace has joined the Company as vice president. Mr. Wallace …

Peter Zerhouni

InDex Pharmaceuticals Holding AB (publ) Interim Report January - September 2017 | PR Newswire | 11/17/2017

Peter Zerhouni , CEO of InDex Pharmaceuticals. CEO statement We are now at the end of the start-up phase for the CONDUCT study, which is InDex’s main focus. The study is currently approved in 10 of the 12 planned countries. Two thirds of the selected 90 clinics have been activated and can enroll patients. The patient recruitment is proceeding according to plan. The objective to have top line results from …

Bristol, Connecticut

Medical Science Manager - Oncology - Bristol-Myers Squibb - Eigenbrakel | PR Newswire | 6/13/2020

Read what people are saying about working here. Bristol-Myers Squibb is a global Biopharma company committed to a single mission: to discover, develop, and deliver innovative medicines focused on helping millions of patients around … e.g. identification and assessment of potential study sites) to support patient recruitment and/or discussions around the safe and effective use of BMS investigational products, as agreed with local medical management and as defined by …

Medical Science Manager - Oncology - Bristol-Myers Squibb - Eigenbrakel | PR Newswire | 6/13/2020

Read what people are saying about working here. Bristol-Myers Squibb is a global Biopharma company committed to a single mission: to discover, develop, and deliver innovative medicines focused on helping millions of patients around … e.g. identification and assessment of potential study sites) to support patient recruitment and/or discussions around the safe and effective use of BMS investigational products, as agreed with local medical management and as defined by …

Denver, Colorado

CORRECTING and REPLACING CU Healthcare Innovation Fund Leads Investment Into ClinOne – a Remote Clinical Trial Patient Management Technology Company | Business Wire | 3/25/2020

Denver and counts UCHealth, the University of Colorado and Children’s Hospital Colorado as limited partners. Through the ClinOne and ClinTrialConnect platforms, the company allows pharmaceutical sponsors, research sites and clinical trial participants to perform and automate key clinical trial operational tasks including clinical trial recruitment, study execution, compliance and patient retention from any location world-wide. ClinOne’s modules span patient recruitment, remote consent (eConsent), patient reported outcomes and surveys (ePRO …

UCHealth Leads Investment Into ClinOne – a Remote Clinical Trial Patient Management Technology Company | Malvern Daily Record | 3/24/2020

Denver and counts UCHealth and Children’s Hospital Colorado as limited partners. Through the ClinOne and ClinTrialConnect platforms, the company allows pharmaceutical sponsors, research sites and clinical trial participants to perform and automate key clinical trial operational tasks including clinical trial recruitment, study execution, compliance and patient retention from any location world-wide. ClinOne’s modules span patient recruitment, remote consent (eConsent), patient reported outcomes and surveys (ePRO), dosing management, remote vital …